Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

This study aimed to evaluate the correlation between adverse events (AEs) and overall survival (OS) in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab (atezo/beva). This was a multicenter study in which 130 patients were enrolled. Hypertension and skin...

Full description

Bibliographic Details
Main Authors: Shigeo Shimose, Hideki Iwamoto, Masatoshi Tanaka, Takashi Niizeki, Masahiko Kajiwara, Satoshi Itano, Etsuko Moriyama, Tomotake Shirono, Yu Noda, Naoki Kamachi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
adverse events
overall survival
hepatocellular carcinoma
progression-free survival
Online Access:https://www.mdpi.com/2072-6694/14/17/4284

Internet

https://www.mdpi.com/2072-6694/14/17/4284

Similar Items